Recursion Pharmaceuticals (RXRX) News Today $5.51 -0.25 (-4.34%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals todayApril 15 at 3:40 AM | markets.businessinsider.comWhy Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?April 15 at 3:40 AM | msn.comAnalysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)April 14 at 1:17 AM | markets.businessinsider.comTop 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRXApril 14 at 1:17 AM | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Here's What HappenedApril 13 at 3:21 AM | americanbankingnews.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.25 Consensus Price Target from BrokeragesApril 13 at 2:28 AM | americanbankingnews.comInvestors Purchase High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)April 13 at 1:54 AM | americanbankingnews.comWhy Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week?April 13 at 1:24 AM | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.6% Higher - Still a Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 21.6% Higher - Time to Buy?April 12 at 9:33 PM | marketbeat.comStock Traders Buy High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of unusually large options trading activity on Friday. Stock investors bought 62,593 call options on the company. This represents an increase of 139% compared to the average volume of 26,225 call options.April 12 at 11:37 AM | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Here's WhyApril 12 at 10:54 AM | marketbeat.comWhy Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday?April 12 at 6:07 AM | msn.comRecursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $8.00 by Analysts at Morgan StanleyApril 12 at 1:55 AM | americanbankingnews.comRecursion: FDA To Replace Animal Testing With AI? - A Small But Necessary WinApril 11, 2025 | seekingalpha.comRecursion Pharma rises, Intel & Five Below fall: Trending TickersApril 11, 2025 | finance.yahoo.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Recommendation of "Hold" from AnalystsShares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have been given a consensus rating of "Hold" by the five research firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and twoApril 11, 2025 | marketbeat.comMorgan Stanley Cuts Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $8.00Morgan Stanley lowered their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday.April 11, 2025 | marketbeat.comRecursion Pharmaceuticals Shares Are Up Today: what's Going On?April 11, 2025 | benzinga.comWhy Recursion Pharmaceuticals Stock Is Skyrocketing TodayApril 11, 2025 | fool.comShould You Buy These 2 Nvidia-Backed Stocks Now?April 11, 2025 | msn.comRecursion Pharmaceuticals price target lowered to $8 from $10 at Morgan StanleyApril 10, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 21.6% - Time to Buy?Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 21.6% - Time to Buy?April 10, 2025 | marketbeat.comRecursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday.April 10, 2025 | marketbeat.comRecursion Pharmaceuticals, Enamine release new tools in its AI/ML platformApril 9, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low - What's Next?Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 52-Week Low - Should You Sell?April 9, 2025 | marketbeat.comRecursion and Enamine Release New AI-Enabled Targeted Compound LibrariesApril 9, 2025 | globenewswire.comRecursion announces first patient dosed in Phase 1 REC-3565 studyApril 8, 2025 | markets.businessinsider.comRecursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell LymphomasApril 8, 2025 | markets.businessinsider.comNorges Bank Buys Shares of 3,465,875 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Norges Bank bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,465,875 shares of the company's stock, valued at approximatelyApril 8, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 90,107 Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Raymond James Financial Inc. purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 90,107 shares of the company's stock, valued at approximately $609,000. A number of oApril 8, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) vs. Omega Therapeutics (NASDAQ:OMGA) Critical ReviewApril 8, 2025 | americanbankingnews.comVanguard Group Inc. Has $229.91 Million Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Vanguard Group Inc. grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 40.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,009,994 shares of the company's stock after purchasing an additional 9,7April 7, 2025 | marketbeat.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership ChangesApril 6, 2025 | finance.yahoo.comHeadlands Technologies LLC Acquires 59,211 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Headlands Technologies LLC lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 196.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,314 shares of thApril 3, 2025 | marketbeat.comDnB Asset Management AS Takes $577,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)DnB Asset Management AS acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 85,365 shares of the company's stock, valued at approximately $577,00April 3, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 12-Month Low - Should You Sell?Recursion Pharmaceuticals (NASDAQ:RXRX) Reaches New 52-Week Low - Time to Sell?April 1, 2025 | marketbeat.comRecursion to Participate in Upcoming Investor ConferenceApril 1, 2025 | globenewswire.comWhy Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged TodayMarch 31, 2025 | fool.comShould Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?March 30, 2025 | fool.comNvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI StocksMarch 30, 2025 | fool.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Acquired by IQ EQ FUND MANAGEMENT IRELAND LtdIQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 143.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 200,470 shares of the company's stock after purchasing anMarch 29, 2025 | marketbeat.comHighTower Advisors LLC Acquires 98,626 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)HighTower Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 408.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 122,770 shares of the company's stock after buying an additionMarch 28, 2025 | marketbeat.comRecursion: A Look At Near-Term Phase 1b And Phase 2 CatalystsMarch 27, 2025 | seekingalpha.comSwiss National Bank Grows Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Swiss National Bank increased its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 36.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 486,700 shares of the company'sMarch 27, 2025 | marketbeat.comIs Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?March 26, 2025 | msn.comWhy Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?March 26, 2025 | msn.comCathie Wood’s ARK Investment buys 205K shares of Recursion Pharmaceuticals todayMarch 26, 2025 | markets.businessinsider.comCathie Wood’s ARK Investment buys 161K shares of Recursion Pharmaceuticals todayMarch 21, 2025 | markets.businessinsider.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 17.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor oMarch 21, 2025 | marketbeat.comPrivium Fund Management B.V. Purchases 41,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)Privium Fund Management B.V. raised its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 52.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 119,000 shares of the company's stock after purchasing an additioMarch 20, 2025 | marketbeat.com Remove Ads Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address RXRX Media Mentions By Week RXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXRX News Sentiment▼0.340.80▲Average Medical News Sentiment RXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXRX Articles This Week▼329▲RXRX Articles Average Week Remove Ads Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Lantheus News Today BridgeBio Pharma News Today Revolution Medicines News Today TG Therapeutics News Today Legend Biotech News Today Blueprint Medicines News Today Sarepta Therapeutics News Today Axsome Therapeutics News Today Krystal Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXRX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RXRX Stock Free RXRX Stock Alerts